Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206955 · ClinicalTrials.gov registry record · Phase 3
Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology
A Phase 3 study of Fontan Palliation, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05206955 is a Phase 3 study of Fontan Palliation that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05206955, a Phase 3 study of Fontan Palliation, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out more about the effectiveness of Tadalafil in improving hemodynamic capabilities, endothelial function, and end-organ function in patients who have previously undergone a Fontan Palliation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tadalafil
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-09-16 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05206955
The ClinicalTrials.gov registry entry for NCT05206955 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fontan Palliation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05206955 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05206955 about?
NCT05206955 is a clinical study titled "Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology". The purpose of this study is to find out more about the effectiveness of Tadalafil in improving hemodynamic capabilities, endothelial function, and end-organ function in patients who have previously undergone a Fontan Palliation.
What is the current status of trial NCT05206955?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2022-09-16. Estimated completion is 2026-11.
What conditions does trial NCT05206955 study?
This clinical trial studies the following conditions: Fontan Palliation.
What interventions are being tested in trial NCT05206955?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT05206955?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206955 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fontan Palliation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.